TAP Consulting’s Jazz Pharmaceuticals JAZZ Stock Holding History

TAP Consulting’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-18	Closed	-$2K	–	345
2021 Q4	$2K	Buy	+18	New	+$2.37K	﹤0.01%	506

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

TAP Consulting's JAZZ Position: Q1 2022 in Review

TAP Consulting sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2022, closing a stake of 18 shares — an estimated $2K sold.

TAP Consulting first reported a position in JAZZ in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 462 funds tracked by Wall St. Rank hold JAZZ as of Q1 2022.

TAP Consulting reported no remaining Jazz Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
TAP Consulting sold 18 Jazz Pharmaceuticals shares in Q1 2022, an estimated $2K.
TAP Consulting first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 1 quarter.
TAP Consulting's Jazz Pharmaceuticals position peaked at $2K in Q4 2021.
462 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2022.

Based on TAP Consulting's 13F filing for Q1 2022, filed 26 Apr 2022.